President Wants Curbs on Extensions of Drug Patents

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 11 No 12
Volume 11
Issue 12

WASHINGTON-President Bush has proposed policy changes to restrict the ability of drug companies to extend their patents past their expiration date. Mr. Bush said current federal laws and regulations try to balance the goals of innovation and accessibility.

WASHINGTON—President Bush has proposed policy changes to restrict the ability of drug companies to extend their patents past their expiration date. Mr. Bush said current federal laws and regulations try to balance the goals of innovation and accessibility.

New drugs have an average of 11 years patent protection before generic versions can be offered. However, companies can extend patent protection by seeking an automatic stay of expiration, which freezes the status quo until the legal questions are answered. Such stays are often based on items as seemingly trivial as the color of a bottle or a combination of ingredients unrelated to the product’s efficacy, the President said.

The FDA will issue a proposed rule that will permit only one automatic stay per generic drug application. Some patents, including those on packaging, will no longer be entitled to protections such as the 30-month automatic stay.

Recent Videos
Educating community practices on CAR T referral and sequencing treatment strategies may help increase CAR T utilization.
The FirstLook liquid biopsy, when used as an adjunct to low-dose CT, may help to address the unmet need of low lung cancer screening utilization.
An 80% sensitivity for lung cancer was observed with the liquid biopsy, with high sensitivity observed for early-stage disease, as well.
9 Experts are featured in this series.
9 Experts are featured in this series.
Harmonizing protocols across the health care system may bolster the feasibility of giving bispecifics to those with lymphoma in a community setting.
2 experts are featured in this series.
Patients who face smoking stigma, perceive a lack of insurance, or have other low-dose CT related concerns may benefit from blood testing for lung cancer.
9 Experts are featured in this series.
Related Content